Rubicon's profit grows twice as fast as its revenue
Net profit surged 83.6% on 36.6% revenue growth. A clean audit and a ₹1.50 dividend seal the year.
— 2 earlier stories on Rubicon Research Ltd. →What's new
- FY26 net profit jumped 83.6% to ₹246.74 cr while revenue grew 36.6% to ₹1,753.96 cr.
- The board recommended a final dividend of ₹1.50 per equity share.
- Deloitte issued an unmodified audit opinion on the results.
Why this matters
The spread between revenue and profit growth is the real story. A 47-percentage-point gap implies a sharp improvement in the cost structure or a more profitable product mix. This converts a good top-line year into a great bottom-line one.
What we're watching
- Whether the high profit growth rate is sustainable into FY27.
- Management commentary on the drivers of the cost improvement.
- How the market prices the stock after this confirmation of growth.
The full read
Rubicon Research's FY26 is a story of profit outrunning sales. Revenue rose 36.6% to ₹1,753.96 crore. Net profit jumped 83.6% to ₹246.74 crore. That 47-point spread is the headline. It signals that more revenue is dropping straight to the bottom line. The specialty pharma company wrapped the year with a strong Q4 revenue of ₹513.92 crore. The board declared a ₹1.50 per share dividend. The audit from Deloitte was clean. The backward-looking numbers are solid. The forward question is whether this cost improvement is the new baseline or a cyclical peak.
Questions answered
- What was the core financial performance for FY26?
- Consolidated revenue grew 36.6% to ₹1,753.96 crore. Net profit grew 83.6% to ₹246.74 crore, a much faster rate that indicates significant profitability improvement.
- How does the quarterly result compare?
- Q4 revenue was ₹513.92 crore. This single quarter accounts for roughly 29% of the full year's revenue, showing a strong finish.
- What about shareholder returns?
- The board recommended a final dividend of ₹1.50 per equity share for the fiscal year.
- Were the results audited?
- Yes, Deloitte Haskins & Sells LLP audited the results and issued an unmodified opinion, finding no material issues.
Rubicon Research Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on RUBICON →- 29 May 2026 · 7:22 PM IST Rubicon's profit grows twice as fast as its revenue
- 3d ago Rubicon's Pithampur plant gets two minor FDA observations in first audit
- 38d ago Rubicon's profit doubled. Its factory is still a year away.